Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal
symptoms in women receiving hormone therapy for breast cancer.
PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing
musculoskeletal symptoms in post-menopausal women with stage I, stage II, or stage III breast
cancer receiving letrozole.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins